兽医疼痛管理市场机会、成长动力、产业趋势分析及 2025-2034 年预测

2024 年全球兽医疼痛管理市场价值为 22 亿美元，预计 2025 年至 2034 年期间的复合年增长率将达到 6.5%。市场成长的动力包括宠物拥有量的增加、动物保健意识的提高以及宠物人性化趋势的日益增强。关节炎、癌症和关节痛等慢性疾病的流行增加了对有效疼痛管理解决方案的需求。此外，兽医外科手术的数量持续增加，进一步增加了对疼痛管理药物和设备的需求。由于动物产品消费量的增加，牲畜健康也成为关注的重点。为了维持生产力，畜牧生产者正在采用疼痛管理解决方案来确保动物的健康。兽医医院的扩张、疼痛管理药物的线上供应量的增加以及远距医疗作用的日益增强进一步促进了市场扩张。

兽医疼痛管理包括用于缓解动物急性和慢性疼痛的药物和设备。 2021 年市值为 19 亿美元，2022 年为 20 亿美元，2023 年为 21 亿美元。就产品而言，药品部分在 2024 年占总市占率的 85.4%。它进一步按类型、给药途径和配销通路分类。按类型划分，该部分包括非类固醇抗发炎药、鸦片类药物、麻醉剂和α-2激动剂。

给药途径分为口服、注射和外用，配销通路包括兽医院药房、零售药局和网路药局。药物在市场上占据主导地位，是因为它们易于获得，并且能够有效控制疼痛和发炎。非类固醇抗发炎药和鸦片类药物因其疗效明确而被广泛使用。由于骨关节炎、关节疾病和癌症等慢性疾病的发生率不断上升，对疼痛管理药物的需求持续上升。药物配方的进步提高了疗效，减少了给药频率，增强了适口性，使其得到了更广泛的接受。

兽医疼痛管理市场也按应用细分，其中关节痛在 2024 年占据最大份额，为 53.7%。该细分市场在 2024 年的价值为 12 亿美元，预计到 2034 年将达到 21 亿美元，复合年增长率为 6.3%。关节疼痛包括骨关节炎和肌肉骨骼疾病等疾病。抗发炎药物和改善病情的骨关节炎药物等先进治疗方法的出现促进了这一领域的扩张。

根据动物类型，市场分为伴侣动物和牲畜动物。伴侣动物细分市场在 2024 年引领市场，预计在预测期内的复合年增长率为 6.4%。此类别包括狗、猫、马和其他伴侣动物。随着宠物的饲养数量不断增加以及其寿命的延长，对兽医疼痛管理解决方案的需求也随之增加。随着宠物年龄的增长，它们更容易患上慢性病，因此需要采取有效的缓解疼痛的措施。宠物保险的成长和兽医费用的增加进一步支持了这一领域的扩张。

2024 年，北美占据全球兽医疼痛管理市场的主导地位，占有 43.9% 的份额。发达的兽医保健基础设施、较高的宠物收养率以及​​大量的牲畜数量增强了该地区的市场实力。美国市场价值在 2021 年为 7.855 亿美元，2022 年成长至 8.175 亿美元，2023 年成长至 8.536 亿美元，进一步巩固了其作为市场成长主要贡献者的地位。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 宠物拥有量和动物保健支出不断增加
    • 动物慢性病盛行率上升
    • 已开发国家对宠物保险的认知有所提高
    • 兽医外科手术激增
    • 兽医学的进步
  • 产业陷阱与挑战
    • 与止痛药相关的副作用
    • 专业技能人才短缺
• 成长潜力分析
• 监管格局
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按产品，2021 年至 2034 年

• 主要趋势
• 药物
  • 按类型
    • 非类固醇抗发炎药
    • 阿片类药物
    • 麻醉药
    • α-2激动剂
    • 其他类型
  • 依给药途径
    • 口服
    • 肠外
    • 外用
  • 按配销通路
    • 兽医院药房
    • 零售药局
    • 网路药局
• 装置
  • 按类型
    • 雷射治疗仪
    • 电磁治疗仪
  • 按最终用途
    • 兽医医院和诊所
    • 学术和研究机构

第六章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 关节疼痛
  • 骨关节炎
  • 肌肉骨骼
• 癌症痛
• 术后疼痛
• 其他应用

第七章：市场估计与预测：依动物类型，2021 年至 2034 年

• 主要趋势
• 伴侣动物
  • 狗
  • 猫
  • 马匹
  • 其他伴侣动物
• 家畜
  • 牛
  • 猪
  • 其他牲畜

第八章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第九章：公司简介

• Alivira Animal Health
• Boehringer Ingelheim
• Ceva Santé Animale
• Chanelle Pharma
• Dechra Pharmaceuticals
• Elanco Animal Health
• K-Laser USA
• Merck
• Multi Radiance Medical
• Norbrook
• Vetoquinol
• Zoetis

The Global Veterinary Pain Management Market was valued at USD 2.2 billion in 2024 and is projected to expand at a 6.5% CAGR from 2025 to 2034. The market growth is driven by increasing pet ownership, rising awareness of animal healthcare, and the growing trend of pet humanization. The prevalence of chronic diseases such as arthritis, cancer, and joint pain has heightened the demand for effective pain management solutions. Additionally, the number of veterinary surgical procedures continues to rise, further boosting the need for pain management drugs and devices. Livestock health has also become a critical focus due to the rising consumption of animal-based products. To maintain productivity, livestock producers are adopting pain management solutions to ensure animal well-being. The expansion of veterinary hospitals, increasing online availability of pain management drugs, and the growing role of telemedicine have further contributed to market expansion.

Veterinary pain management includes drugs and devices used to relieve acute and chronic pain in animals. In 2021, the market was valued at USD 1.9 billion, followed by USD 2 billion in 2022 and USD 2.1 billion in 2023. In terms of products, the drugs segment accounted for 85.4% of the total market share in 2024. It is further categorized by type, route of administration, and distribution channel. By type, the segment includes NSAIDs, opioids, anesthetics, and alpha-2 agonists.

The route of administration is divided into oral, parenteral, and topical, while the distribution channel includes veterinary hospital pharmacies, retail pharmacies, and online pharmacies. The dominance of drugs in the market is attributed to their easy availability and effectiveness in managing pain and inflammation. NSAIDs and opioids are widely used due to their well-established efficacy. The demand for pain management drugs continues to rise due to the increasing prevalence of chronic diseases such as osteoarthritis, joint disorders, and cancer. Advancements in drug formulations have improved efficacy, reduced dosage frequency, and enhanced palatability, making them more widely accepted.

The veterinary pain management market is also segmented by application, with joint pain holding the largest share of 53.7% in 2024. This segment was valued at USD 1.2 billion in 2024 and is projected to reach USD 2.1 billion by 2034 at a CAGR of 6.3%. Joint pain includes conditions such as osteoarthritis and musculoskeletal disorders. The availability of advanced treatments, including anti-inflammatory drugs and disease-modifying osteoarthritis drugs, has contributed to the expansion of this segment.

By animal type, the market is classified into companion animals and livestock animals. The companion animals segment led the market in 2024 and is expected to grow at a 6.4% CAGR during the forecast period. This category includes dogs, cats, horses, and other companion animals. The increasing adoption of pets and their longer lifespan have heightened the demand for veterinary pain management solutions. As pets age, they become more susceptible to chronic conditions, necessitating effective pain relief measures. The growth of pet insurance and rising veterinary expenditures have further supported the expansion of this segment.

North America dominated the global veterinary pain management market in 2024, holding a 43.9% share. The well-developed veterinary healthcare infrastructure, high pet adoption rates, and substantial livestock population contribute to the region's market strength. The U.S. market, which was valued at USD 785.5 million in 2021, grew to USD 817.5 million in 2022 and USD 853.6 million in 2023, further solidifying its position as the leading contributor to market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising pet ownership and animal healthcare spending
    • 3.2.1.2 Rising prevalence of chronic diseases in animals
    • 3.2.1.3 Increased awareness about pet insurance in developed countries
    • 3.2.1.4 Surge in veterinary surgical procedures
    • 3.2.1.5 Advancements in veterinary medicine
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Side effects associated with pain medications
    • 3.2.2.2 Shortage of skilled professionals
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 By type
    • 5.2.1.1 NSAIDs
    • 5.2.1.2 Opioids
    • 5.2.1.3 Anesthetics
    • 5.2.1.4 Alpha-2 agonists
    • 5.2.1.5 Other types
  • 5.2.2 By Route of Administration
    • 5.2.2.1 Oral
    • 5.2.2.2 Parenteral
    • 5.2.2.3 Topical
  • 5.2.3 By Distribution channel
    • 5.2.3.1 Veterinary hospital pharmacies
    • 5.2.3.2 Retail pharmacies
    • 5.2.3.3 Online pharmacies
• 5.3 Devices
  • 5.3.1 By Type
    • 5.3.1.1 Laser therapy devices
    • 5.3.1.2 Electromagnetic therapy devices
  • 5.3.2 By End Use
    • 5.3.2.1 Veterinary hospitals & clinics
    • 5.3.2.2 Academic and research institutes

Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Joint pain
  • 6.2.1 Osteoarthritis
  • 6.2.2 Musculoskeletal
• 6.3 Cancer pain
• 6.4 Postoperative pain
• 6.5 Other applications

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Companion animals
  • 7.2.1 Dogs
  • 7.2.2 Cats
  • 7.2.3 Horses
  • 7.2.4 Other companion animals
• 7.3 Livestock animals
  • 7.3.1 Cattle
  • 7.3.2 Swine
  • 7.3.3 Other livestock animals

Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Italy
  • 8.3.5 Spain
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Alivira Animal Health
• 9.2 Boehringer Ingelheim
• 9.3 Ceva Santé Animale
• 9.4 Chanelle Pharma
• 9.5 Dechra Pharmaceuticals
• 9.6 Elanco Animal Health
• 9.7 K-Laser USA
• 9.8 Merck
• 9.9 Multi Radiance Medical
• 9.10 Norbrook
• 9.11 Vetoquinol
• 9.12 Zoetis